Table 4.
Variety of approaches among COVID-19 vaccine candidates until 24 November 2021
| Vaccine Category | Phase |
Total | ||||||
|---|---|---|---|---|---|---|---|---|
| Pre-Clinical | I | I/II | II | II/III | III | Authorized | ||
| DNA-based | 10 | 4 | 6 | - | 2 | 1 | - | 23 |
| Inactivated virus | 5 | 2 | 3 | - | 1 | 11 | - | 22 |
| Live attenuated virus | 2 | 2 | - | - | - | - | - | 4 |
| Non-replicating viral vector | 19 | 5 | 3 | 1 | 2 | 2 | 2 | 34 |
| Protein subunit | 60 | 7 | 9 | 4 | 2 | 10 | - | 92 |
| Replicating bacterial vector | 2 | - | - | - | - | - | - | 2 |
| Replicating viral vector | 17 | 1 | 4 | 1 | - | - | - | 23 |
| RNA-based vaccine | 22 | 4 | 3 | 2 | 1 | - | 2 | 34 |
| Unknown | 15 | - | - | - | - | - | - | 15 |
| Virus-like particle | 18 | 2 | 2 | - | 1 | - | - | 23 |
| Total | 170 | 27 | 30 | 8 | 9 | 24 | 4 | 272 |